Law360, New York (May 28, 2009, 12:00 AM ET) -- Express Scripts Inc. announced Thursday that its planned $4.68 billion acquisition of pharmacy benefits manager NextRX LLC was moving ahead full steam after a mandatory antitrust review period came to an end with no action taken by regulators.
St. Louis-based Express Scripts said the waiting period required under the Hart-Scott-Rodino Act in connection with its premerger notification filing relating to its proposed acquisition of NextRx — a subsidiary of health insurer WellPoint Inc. — expired on Wednesday, representing a “significant step forward” toward completion of the...
$4.7B Express Scripts-NextRX Merger Accelerates
To view the full article, take a free trial now.
